- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and li...
Transition Therapeutics Competitors or Alternatives
Transition Therapeutics's top competitors include Minerva Neurosciences, Voyager and Cynapsus.
Transition Therapeutics VS Minerva Neurosciences
Minerva Neurosciences is Transition Therapeutics's biggest rival. Minerva Neurosciences was founded in Waltham, Massachusetts} in 2007. Like Transition Therapeutics, Minerva Neurosciences also competes in the Chemicals, Metals & Mining sector. Compared to Transition Therapeutics, Minerva Neurosciences generates $23.3M more revenue.
Transition Therapeutics VS Voyager
Voyager is Transition Therapeutics's #2 rival. Voyager's headquarters is in Lexington, Massachusetts, and was founded in 2013. Like Transition Therapeutics, Voyager also competes in the Chemicals, Metals & Mining space. Voyager generates 446% of Transition Therapeutics's revenue.
Looking for similar companies to Transition Therapeutics?
Similar Companies
Specialty Chemicals companies in Toronto
See 42 companies
Chemicals, Metals & Mining companies in TorontoSee 730 companies
Specialty Chemicals companies in CanadaSee 466 companies
Specialty Chemicals companies with employees in 1-25 rangeSee 692 companies
Specialty Chemicals companies in OntarioSee 185 companies
Specialty Chemicals companies with revenue in $5.0-25M rangeSee 1,253 companies
Chemicals, Metals & Mining companies in OntarioSee 2,318 companies
Companies in Toronto with employees in 1-25 rangeSee 4,337 companies
Specialty Chemicals companies in North AmericaSee 4,830 companies
Trending News for Transition Therapeutics and Transition Therapeutics's Competitors
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial. The post Vertex halts development of...
NEW YORK, March 31, 2025 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "C...
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of ge...
Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd. read more...
Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025...
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early loo...
BOSTON, MA, Arbor Biotechnologies announced the closing of a $73.9 million Series C financing....
Ayrmid's offer is 50% higher than bluebird's previously announced deal with Carlyle and SK Capital Partners....
Frequently Asked Questions about Transition Therapeutics
Who are Transition Therapeutics's top competitors?
Transition Therapeutics's top 3 competitors are Minerva Neurosciences, Voyager, Cynapsus.Who is similar to Transition Therapeutics?
Minerva Neurosciences is the most similar to Transition Therapeutics. Voyager and Cynapsus are also similar to Transition Therapeutics.
Are Transition Therapeutics and Minerva Neurosciences competitors?
Yes, Minerva Neurosciences is one of Transition Therapeutics’s top competitors.